Biotech News
Related news
AXSMAxsome2026-10-07 11:00 EST
Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2
AXSMAxsome2026-09-17 11:00 EST
Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026
HRMYHarmony Biosciences2026-11-19 13:05 EST
Harmony Biosciences to Participate in Upcoming Investor Conferences
IKTInhibikase Therapeutics2026-10-27 12:00 EST
Inhibikase Therapeutics Announces Participation in Upcoming Investor Conferences During November 2026
GANXGain Therapeutics2026-11-05 12:00 EST
Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences
XENEXenon2026-11-03 21:01 EST
Xenon to Present at Upcoming Investor Conferences
ALKSAlkermes plc2026-11-03 21:00 EST
Alkermes to Present at Upcoming Investor Conferences
CLNNClene Inc.2026-09-22 12:00 EST
Clene to Present at Upcoming Investor Conferences
CGTXCognition Therapeutics2026-11-09 12:30 EST
Cognition Therapeutics Invited to Participate in 2026 Jefferies Global Healthcare Conference
GANXGain Therapeutics2026-09-17 11:00 EST
Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference
Axsome
CNS Commercial Portfolio Axsome Therapeutics develops and commercializes medicines for central nervous system disorders. Its business combines marketed products in depression, migraine and sleep disorders with a pipeline spanning psychiatry and neurology. AUVELITY AUVELITY is an oral NMDA receptor antagonist and sigma-1 receptor agonist...
Recent company news
AXSMAxsome2026-11-19 12:00 EST
Axsome Therapeutics to Participate in Upcoming Investor Conferences
AXSMAxsome2026-11-03 12:00 EST
Axsome Therapeutics to Participate in Upcoming Investor Conferences
AXSMAxsome2026-10-07 11:00 EST
Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2
AXSMAxsome2026-09-21 11:00 EST
Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day
AXSMAxsome2026-09-17 11:00 EST
Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026
Stock data
- Close
- 135.68 USD
- Market cap
- 11.43B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States
